476 related articles for article (PubMed ID: 31331639)
1. Tumor Vasculatures: A New Target for Cancer Immunotherapy.
Liu Z; Wang Y; Huang Y; Kim BYS; Shan H; Wu D; Jiang W
Trends Pharmacol Sci; 2019 Sep; 40(9):613-623. PubMed ID: 31331639
[TBL] [Abstract][Full Text] [Related]
2. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
3. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
4. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
[TBL] [Abstract][Full Text] [Related]
5. Improving immune-vascular crosstalk for cancer immunotherapy.
Huang Y; Kim BYS; Chan CK; Hahn SM; Weissman IL; Jiang W
Nat Rev Immunol; 2018 Mar; 18(3):195-203. PubMed ID: 29332937
[TBL] [Abstract][Full Text] [Related]
6. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer.
Missiaen R; Mazzone M; Bergers G
Semin Cancer Biol; 2018 Oct; 52(Pt 2):107-116. PubMed ID: 29935312
[TBL] [Abstract][Full Text] [Related]
7. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Lee WS; Yang H; Chon HJ; Kim C
Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of immunotherapies and nanomedicine to better normalize angiogenesis-based cancer treatment.
Jasim SA; Farber IM; Noraldeen SAM; Bansal P; Alsaab HO; Abdullaev B; Alkhafaji AT; Alawadi AH; Hamzah HF; Mohammed BA
Microvasc Res; 2024 Jul; 154():104691. PubMed ID: 38703993
[TBL] [Abstract][Full Text] [Related]
9. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS; Schmittnaegel M; Rigamonti N; Pais-Ferreira D; Mueller P; Buchi M; Ooi CH; Kreuzaler M; Hirschmann P; Guichard A; Rieder N; Bill R; Herting F; Kienast Y; Dirnhofer S; Klein C; Hoves S; Ries CH; Corse E; De Palma M; Zippelius A
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):541-551. PubMed ID: 31889004
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic Targeting of Tumor-Associated Blood Vessels.
Fabian KL; Storkus WJ
Adv Exp Med Biol; 2017; 1036():191-211. PubMed ID: 29275473
[TBL] [Abstract][Full Text] [Related]
11. Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity.
Tzeng HT; Huang YJ
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901858
[TBL] [Abstract][Full Text] [Related]
12. [Vascular normalization and cancer immunotherapy].
Zeng J; Yuan D; Liu H; Song Y
Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):273-6. PubMed ID: 24667268
[TBL] [Abstract][Full Text] [Related]
13. Normalization of the vasculature for treatment of cancer and other diseases.
Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
[TBL] [Abstract][Full Text] [Related]
14. [Immune therapy and tumor angiogenesis].
Takakura N
Rinsho Ketsueki; 2020; 61(9):1440-1445. PubMed ID: 33162547
[TBL] [Abstract][Full Text] [Related]
15. Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy.
Andersson P; Ostheimer C
Front Immunol; 2019; 10():2083. PubMed ID: 31555290
[No Abstract] [Full Text] [Related]
16. Tumor angiogenesis and vascular normalization: alternative therapeutic targets.
Viallard C; Larrivée B
Angiogenesis; 2017 Nov; 20(4):409-426. PubMed ID: 28660302
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenesis: Opening a new window for immunotherapy.
Guo F; Cui J
Life Sci; 2020 Oct; 258():118163. PubMed ID: 32738363
[TBL] [Abstract][Full Text] [Related]
18. Inducing vascular normalization: A promising strategy for immunotherapy.
Luo X; Zou W; Wei Z; Yu S; Zhao Y; Wu Y; Wang A; Lu Y
Int Immunopharmacol; 2022 Nov; 112():109167. PubMed ID: 36037653
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan RR; Griffioen AW; Duda DG
Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
[TBL] [Abstract][Full Text] [Related]
20. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
Melaiu O; Vanni G; Portarena I; Pistolese CA; Anemona L; Pomella S; Bei R; Buonomo OC; Roselli M; Mauriello A; Barillari G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]